Stockscreener 앱 받기
1.32
11.41%
-0.17
시간 외 거래:
1.33
0.01
+0.76%
Biomea Fusion Inc 주식(BMEA)의 최신 뉴스
Form 424B5 Biomea Fusion Inc For: 27 September By Investing.com - Investing.com Nigeria
BMEA Stock Slides As Biomea Fusion Pulls Equity Offering - timothysykes.com
Biomea Fusion Shares Fall 19% After Hours: Here’s Why - webull.com
Biomea Fusion scraps equity offering, delays study data - scanx.trade
Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure (BMEA) - Seeking Alpha
Biomea Fusion Scraps Stock Offering, Sending Shares Down 19% After Hours - finance.biggo.com
Biomea Fusion Shares Fall After Terminating Proposed Public Offering - marketscreener.com
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data - benzinga.com
Biomea Fusion Completes Phase 1 BMF-500 Trial in Acute Leukemia: What Investors Should Watch Next - TipRanks
Biomea stock slips after delaying trial readout (BMEA:NASDAQ) - Seeking Alpha
Biomea Fusion stock ticks up after canceling public offering By Investing.com - Investing.com Nigeria
Biomea Fusion stock ticks up after canceling public offering - Investing.com
Biomea Fusion terminates proposed public offering By Investing.com - Investing.com Canada
Biomea Fusion terminates proposed public offering - Investing.com
Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities - TradingView
Biomea Fusion Announces Termination of Proposed Public Offering of Securities - globenewswire.com
Biomea Fusion stock tumbles on public offering launch - Investing.com
Biomea Fusion stock tumbles on public offering launch By Investing.com - Investing.com Nigeria
Biomea Fusion Updates Timeline for BMF-650 Phase I Data - TipRanks
Biomea Fusion announces public offering of common stock - Investing.com
Biomea Fusion announces public offering of common stock By Investing.com - Investing.com Nigeria
Biomea Fusion Proposes Public Offering of Common Stock, Pre-Funded Warrants - marketscreener.com
Biomea Fusion Announces Proposed Public Offering of Securities - The Manila Times
Biomea Fusion announces proposed public offering of shares - TradingView
No size or terms are set for Biomea Fusion's share offering. Its underwriter may buy up to 15% more. - Stock Titan
BMEA Stock Price and Chart — NASDAQ:BMEA - TradingView
Biomea Fusion, Inc.(NasdaqGS: BMEA) dropped from S&P Global BMI Index - marketscreener.com
Biomea Fusion Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock GainRevenue Recognition Risk - dars.gov.et
Biomea Fusion, Inc. (BMEA) Presents at H.C. Wainwright 28th Annual Global Investment ConferenceSlideshow (NASDAQ:BMEA) 2026-09-16 - Seeking Alpha
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright - Yahoo Finance
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next - TipRanks
Biomea Fusion to Participate in Upcoming Investor Conferences - Investing News Network
BMEA Surges 6.85%: Biomea Fusion Approaches Key $1.88 ResistanceQuote Data - vinanet.vn
Biomea Fusion (BMEA) Rallies 4.46% to $1.75 as Clinical-Stage Biotech Tests ResistanceSize Factor - dars.gov.et
BMEA Should I Buy - Intellectia AI
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Here's Why We're Watching Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation - Sahm
Biomea Shares Rise After Completing Enrollment in Diabetes Trial - marketscreener.com
Biomea Fusion stock surges on diabetes trial enrollment completion By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Biomea Fusion stock rating on trial enrollment By Investing.com - Investing.com UK
Why is Biomea Fusion stock climbing today? By Investing.com - Investing.com India
Biomea Fusion completes enrollment in diabetes trial By Investing.com - Investing.com Canada
Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes - TradingView
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it? - TradingView
Biomea (BMEA) Q2 2026 Results: EPS Prints Above Forecast in the Latest Session; Share Response: The Stock Records a 19.71% Increase for the Current SessionNegative Surprise Momentum - dars.gov.et
Biomea (BMEA) Quarterly Results: Profit Per Share Clears Its Benchmark at the Close; Investor Response - vinanet.vn
Biomea Fusion begins dosing first participant in OPAL study arm for new combination therapy - Traders Union
Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure - Kalkine Media
Biomea Fusion shares new insights on three stages of type 1 diabetes in expert webinar - Traders Union
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity - Investing News Network
Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com - Investing.com Canada
Biomea Fusion doses first patient in icovamenib-semaglutide study - Investing.com
3.06%
2.55%
자본화:
|
볼륨(24시간):